论文部分内容阅读
目的探讨89SrCl2重复治疗转移性骨肿瘤的价值。方法对经单光子发射计算机断层成像术(SPECT)全身骨扫描确诊的71例转移性骨肿瘤患者进行每例至少2次的89SrCl2重复治疗,对患者骨痛缓解、转移灶治疗情况及安全性进行研究。结果71例经89SrCl2重复治疗的转移性骨肿瘤患者中,骨痛缓解率与原发癌症有关且较单次治疗高,重复治疗对患者安全,但转移灶治疗有效率无改变。结论89SrCl2重复治疗转移性骨肿瘤可安全的提高骨痛缓解率,但不能提高转移灶治疗有效率。
Objective To investigate the value of 89SrCl2 repeated treatment of metastatic bone tumors. Methods A total of 71 patients with metastatic bone tumors diagnosed by single photon emission computed tomography (SPECT) bone scintigraphy were treated with 89SrCl2 at least twice every time. The treatment of patients with bone pain, the treatment of metastases and the safety were performed the study. Results 71 cases of 89SrCl2 repeated treatment of metastatic bone cancer patients, the pain relief rate associated with primary cancer and higher than the single treatment, repeated treatment of patients with safety, but no change in the efficiency of treatment of metastases. Conclusion 89SrCl2 repeated treatment of metastatic bone tumors can safely improve the pain relief rate, but can not improve the efficiency of treatment of metastases.